Dilantin (Phenytoin Sodium Extended) Patent Expiration, LOE Window & CMS Spending

Dilantin (Phenytoin Sodium Extended) by Pfizer: Off-Patent Genericized (AB Competition), 9 AB generics, $32.1M 2024 CMS Part D & Medicaid spend, and 13 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN010151 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$32.1M
2024 Medicare Part D Spend$28.3M
2024 Medicaid Spend$3.8M
Reported Wholesale Price Change (CA SB 17)13 WAC filings (max 17.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.